Qin L, Chen Y, Lesher B, Qifa L, Charbonneau C, Earnshaw SR, McDade CL, Mao N, Gao X. Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected aspergillus invasive fungal infections in China. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA. [abstract] Value Health. 2015 May; 18(3):A237.
Hicks K, Earnshaw S, McDade C, Shaw JW, Cifaldi MA. Benefit-risk analysis of adalimumab and alternative treatments for moderate to severe rheumatoid arthritis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 13, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A439-40.
Earnshaw SR, McDade CL, Zanotti G, Farkouh R, Strutton D. Cost-effectiveness of 2+1 dosing of 13-valent pneumococcal conjugate vaccine compared with 2+1 dosing of 10-valent conjugate vaccine in preventing pneumococcal disease in Canada. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A275.
Earnshaw S, Pignone M, Fendrick AM, Scheiman J, McDade C. Cost-effectiveness of proton pump inhibitors for prevention of gastrointestinal adverse events when using aspirin for primary cardiovascular prevention. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A166.
Earnshaw S, McDade CL, Black L, Kattan M. Cost-effectiveness of chemoprevention with dutasteride based on results from the REDUCE clinical trial. Poster presented at the 2009 ISPOR 12th Annual European Congress; October 28, 2009. [abstract] Value Health. 2009 Oct; 12(7):A371.